On the chart you can see the default numbers in dynamics for Kura Oncology, Inc. (KURA). Companys revenue shows the average of 0 M which is 0.000 % gowth. The average gross profit for the whole period is -0.156 M which is -0.094 %. The average gross profit ratio is 0.000 %. The net income growth for the company last year performance is 0.122 % which equals -8.281 % % on average for the whole company history.,
Diving into the fiscal trajectory of Kura Oncology, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.016. In the realm of current assets, KURA clocks in at 432.481 in the reporting currency. A significant portion of these assets, precisely 423.957, is held in cash and short-term investments. This segment shows a change of -0.032% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0.2, if any, in the reporting currency. This indicates a difference of -4.762% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 9.332 in the reporting currency. This figure signifies a year_over_year change of 0.226%. Shareholder value, as depicted by the total shareholder equity, is valued at 397.273 in the reporting currency. The year over year change in this aspect is -1.698%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2.8, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.
The financial landscape of Kura Oncology, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.129. The company recently extended its share capital by issuing 94.78, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 10.33 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 15557000.000 in the reporting currency. This is a shift of -0.523 from the previous year. In the same period, the company recorded 0.85, 15.56, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 94.78, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Kura Oncology, Inc.'s revenue saw a change of 0.000% compared with the previous period. The gross profit of KURA is reported to be -0.85. The company's operating expenses are 164.96, showing a change of 17.939% from the last year. The expenses for depreciation and amortization are 0.85, which is a 0.119% change from the last accounting period. Operating expenses are reported to be 164.96, which shows a 17.939% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.179% year-over-year growth. The operating income is -165.8, which shows a 0.179% change when compared to the previous year. The change in the net income is 0.122%. The net income for the last year was -152.63.
